Becton Dickinson Valuation
Is BDX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BDX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BDX * (MX$4709) is trading below our estimate of fair value (MX$5729.37)
Significantly Below Fair Value: BDX * is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BDX *?
Key metric: As BDX * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BDX *'s PE Ratio? | |
|---|---|
| PE Ratio | 44x |
| Earnings | US$1.46b |
| Market Cap | US$64.82b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.2x |
| Enterprise Value/EBITDA | 16.2x |
| PEG Ratio | 2.9x |
Price to Earnings Ratio vs Peers
How does BDX *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 26.2x | ||
SHL Siemens Healthineers | 29.4x | 14.2% | €57.1b |
MDT Medtronic | 25.8x | 10.1% | US$109.9b |
EW Edwards Lifesciences | 27.1x | 1.9% | US$42.2b |
GEHC GE HealthCare Technologies | 22.6x | 11.4% | US$37.7b |
BDX * Becton Dickinson | 44x | 15.3% | Mex$64.8b |
Price-To-Earnings vs Peers: BDX * is expensive based on its Price-To-Earnings Ratio (44x) compared to the peer average (26.2x).
Price to Earnings Ratio vs Industry
How does BDX *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
| 10 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 10 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: BDX * is expensive based on its Price-To-Earnings Ratio (44x) compared to the Global Medical Equipment industry average (28x).
Price to Earnings Ratio vs Fair Ratio
What is BDX *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 44x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BDX *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$4,709.00 | Mex$5,738.25 +21.9% | 8.5% | Mex$6,686.37 | Mex$5,103.07 | n/a | 16 |
| Nov ’25 | Mex$4,642.50 | Mex$5,434.45 +17.1% | 8.4% | Mex$6,274.09 | Mex$4,633.18 | n/a | 16 |
| Oct ’25 | Mex$4,532.75 | Mex$5,507.75 +21.5% | 8.6% | Mex$6,374.29 | Mex$4,707.17 | n/a | 16 |
| Sep ’25 | Mex$4,675.00 | Mex$5,158.31 +10.3% | 7.9% | Mex$6,059.76 | Mex$4,474.90 | n/a | 16 |
| Aug ’25 | Mex$4,298.00 | Mex$5,198.66 +21.0% | 7.9% | Mex$6,100.93 | Mex$4,505.30 | n/a | 16 |
| Jul ’25 | Mex$4,182.80 | Mex$5,154.69 +23.2% | 8.1% | Mex$6,000.57 | Mex$4,431.19 | n/a | 16 |
| Jun ’25 | Mex$3,764.15 | Mex$4,736.57 +25.8% | 8.1% | Mex$5,523.73 | Mex$4,079.06 | n/a | 16 |
| May ’25 | Mex$3,992.99 | Mex$4,732.29 +18.5% | 8.2% | Mex$5,513.24 | Mex$4,071.31 | n/a | 14 |
| Apr ’25 | Mex$4,074.30 | Mex$4,716.63 +15.8% | 7.6% | Mex$5,438.58 | Mex$4,016.18 | n/a | 14 |
| Mar ’25 | Mex$4,241.55 | Mex$4,867.98 +14.8% | 7.5% | Mex$5,589.12 | Mex$4,127.35 | n/a | 15 |
| Feb ’25 | Mex$4,154.75 | Mex$4,877.63 +17.4% | 7.4% | Mex$5,553.11 | Mex$4,100.76 | n/a | 15 |
| Jan ’25 | n/a | Mex$4,962.05 0% | 7.5% | Mex$5,677.07 | Mex$4,192.30 | n/a | 15 |
| Dec ’24 | n/a | Mex$5,032.69 0% | 7.7% | Mex$5,717.63 | Mex$4,222.25 | n/a | 15 |
| Nov ’24 | Mex$4,542.11 | Mex$5,420.36 +19.3% | 5.2% | Mex$5,847.37 | Mex$4,875.80 | Mex$4,642.50 | 15 |
| Oct ’24 | Mex$4,595.03 | Mex$5,181.28 +12.8% | 5.2% | Mex$5,582.04 | Mex$4,654.56 | Mex$4,532.75 | 15 |
| Sep ’24 | Mex$4,733.03 | Mex$5,083.93 +7.4% | 5.3% | Mex$5,499.68 | Mex$4,585.89 | Mex$4,675.00 | 16 |
| Aug ’24 | Mex$4,675.00 | Mex$4,912.82 +5.1% | 6.5% | Mex$5,469.33 | Mex$4,375.46 | Mex$4,298.00 | 16 |
| Jul ’24 | Mex$4,438.11 | Mex$5,002.63 +12.7% | 4.8% | Mex$5,345.12 | Mex$4,541.60 | Mex$4,182.80 | 15 |
| Jun ’24 | Mex$4,240.30 | Mex$5,080.14 +19.8% | 4.9% | Mex$5,440.47 | Mex$4,622.62 | Mex$3,764.15 | 15 |
| May ’24 | Mex$4,716.11 | Mex$5,030.87 +6.7% | 6.8% | Mex$5,520.36 | Mex$4,419.90 | Mex$3,992.99 | 15 |
| Apr ’24 | Mex$4,411.13 | Mex$5,244.20 +18.9% | 6.7% | Mex$5,804.51 | Mex$4,647.41 | Mex$4,074.30 | 13 |
| Mar ’24 | Mex$4,369.00 | Mex$5,244.20 +20.0% | 6.7% | Mex$5,804.51 | Mex$4,647.41 | Mex$4,241.55 | 13 |
| Feb ’24 | Mex$4,629.01 | Mex$5,138.73 +11.0% | 6.6% | Mex$5,777.80 | Mex$4,626.02 | Mex$4,154.75 | 13 |
| Jan ’24 | n/a | Mex$5,234.90 0% | 6.5% | Mex$5,977.16 | Mex$4,785.63 | n/a | 13 |
| Dec ’23 | n/a | Mex$5,134.36 0% | 8.1% | Mex$5,941.82 | Mex$4,271.89 | n/a | 12 |
| Nov ’23 | Mex$4,693.08 | Mex$5,575.69 +18.8% | 8.1% | Mex$6,405.68 | Mex$4,558.27 | Mex$4,542.11 | 12 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.